Baseret på kliniske studier, der inkluderede 1725 patienter, forventes omkring 8% af de patienter, der bliver behandlet med NeoRecormon at opleve bivirkninger.
Based on results from clinical trials including 1725 patients approximately 8% of patients treated with NeoRecormon are expected to experience adverse reactions.